Literature DB >> 23135264

Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies.

Jean-Jacques Rouby1, Belaïd Bouhemad, Antoine Monsel, Hélène Brisson, Charlotte Arbelot, Qin Lu.   

Abstract

The aim of this review is to perform a critical analysis of experimental studies on aerosolized antibiotics and draw lessons for clinical use in patients with ventilator-associated pneumonia. Ultrasonic or vibrating plate nebulizers should be preferred to jet nebulizers. During the nebulization period, specific ventilator settings aimed at decreasing flow turbulence should be used, and discoordination with the ventilator should be avoided. The appropriate dose of aerosolized antibiotic can be determined as the intravenous dose plus extrapulmonary deposition. If these conditions are strictly respected, then high lung tissue deposition associated with rapid and efficient bacterial killing can be expected. For aerosolized aminoglycosides and cephalosporins, a decrease in systemic exposure leading to reduced toxicity is not proven by experimental studies. Aerosolized colistin, however, does not easily cross the alveolar-capillary membrane even in the presence of severe lung infection, and high doses can be delivered by nebulization without significant systemic exposure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23135264     DOI: 10.1097/ALN.0b013e3182755d7a

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  21 in total

Review 1.  Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.

Authors:  Garyphallia Poulakou; Dimitrios K Matthaiou; David P Nicolau; Georgios Siakallis; George Dimopoulos
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  How to Manage Pseudomonas aeruginosa Infections.

Authors:  Matthaios Papadimitriou-Olivgeris; Damien Jacot; Benoit Guery
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

3.  Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients.

Authors:  Stephan Ehrmann; Ferran Roche-Campo; Laetitia Bodet-Contentin; Keyvan Razazi; Jonathan Dugernier; Josep Trenado-Alvarez; Alexis Donzeau; François Vermeulen; David Thévoz; Metaxia Papanikolaou; Antoine Edelson; Héctor León Yoshido; Lise Piquilloud; Karim Lakhal; Carlos Lopes; Carlos Vicent; Arnaud Desachy; Gabriela Apiou-Sbirlea; Daniel Isabey; Laurent Brochard
Journal:  Intensive Care Med       Date:  2015-11-24       Impact factor: 17.440

4.  A more clinically relevant model of ventilator-associated pneumonia?

Authors:  Brant M Wagener; Jean-Francois Pittet
Journal:  Anesthesiology       Date:  2014-05       Impact factor: 7.892

5.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

Review 6.  Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis.

Authors:  Fernando G Zampieri; Antonio P Nassar; Dimitri Gusmao-Flores; Leandro U Taniguchi; Antoni Torres; Otavio T Ranzani
Journal:  Crit Care       Date:  2015-04-07       Impact factor: 9.097

Review 7.  Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient.

Authors:  Matteo Bassetti; Charles-Edouard Luyt; David P Nicolau; Jérôme Pugin
Journal:  Ann Intensive Care       Date:  2016-04-18       Impact factor: 6.925

8.  Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial.

Authors:  Sami Abdellatif; Ahlem Trifi; Foued Daly; Khaoula Mahjoub; Rochdi Nasri; Salah Ben Lakhal
Journal:  Ann Intensive Care       Date:  2016-03-31       Impact factor: 6.925

Review 9.  Advances in antibiotic therapy in the critically ill.

Authors:  Jean-Louis Vincent; Matteo Bassetti; Bruno François; George Karam; Jean Chastre; Antoni Torres; Jason A Roberts; Fabio S Taccone; Jordi Rello; Thierry Calandra; Daniel De Backer; Tobias Welte; Massimo Antonelli
Journal:  Crit Care       Date:  2016-05-17       Impact factor: 9.097

10.  Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study.

Authors:  Jonathan Dugernier; Gregory Reychler; Xavier Wittebole; Jean Roeseler; Virginie Depoortere; Thierry Sottiaux; Jean-Bernard Michotte; Rita Vanbever; Thierry Dugernier; Pierre Goffette; Marie-Agnes Docquier; Christian Raftopoulos; Philippe Hantson; François Jamar; Pierre-François Laterre
Journal:  Ann Intensive Care       Date:  2016-07-22       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.